Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study

Wille K, Stegelmann F, Busen H, Fuchs C, Schauer S, Sadjadian P, Becker T, Kolatzki V, Doehner H, Doehner K, Griesshammer M (2019)
In: ONCOLOGY RESEARCH AND TREATMENT., 42(Suppl. 4). Basel: Karger: 96.

Kurzbeitrag Konferenz / Poster | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Wille, K.; Stegelmann, F.; Busen, H.; Fuchs, ChristianeUniBi ; Schauer, S.; Sadjadian, P.; Becker, T.; Kolatzki, V.; Doehner, H.; Doehner, K.; Griesshammer, M.
Erscheinungsjahr
2019
Titel des Konferenzbandes
ONCOLOGY RESEARCH AND TREATMENT
Band
42
Ausgabe
Suppl. 4
Seite(n)
96
ISSN
2296-5270
eISSN
2296-5262
Page URI
https://pub.uni-bielefeld.de/record/2946521

Zitieren

Wille K, Stegelmann F, Busen H, et al. Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. In: ONCOLOGY RESEARCH AND TREATMENT. Vol 42. Basel: Karger; 2019: 96.
Wille, K., Stegelmann, F., Busen, H., Fuchs, C., Schauer, S., Sadjadian, P., Becker, T., et al. (2019). Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. ONCOLOGY RESEARCH AND TREATMENT, 42, 96. Basel: Karger.
Wille, K., Stegelmann, F., Busen, H., Fuchs, C., Schauer, S., Sadjadian, P., Becker, T., Kolatzki, V., Doehner, H., Doehner, K., et al. (2019). “Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study” in ONCOLOGY RESEARCH AND TREATMENT, vol. 42, (Basel: Karger), 96.
Wille, K., et al., 2019. Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. In ONCOLOGY RESEARCH AND TREATMENT. no.42 Basel: Karger, pp. 96.
K. Wille, et al., “Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study”, ONCOLOGY RESEARCH AND TREATMENT, vol. 42, Basel: Karger, 2019, pp.96.
Wille, K., Stegelmann, F., Busen, H., Fuchs, C., Schauer, S., Sadjadian, P., Becker, T., Kolatzki, V., Doehner, H., Doehner, K., Griesshammer, M.: Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study. ONCOLOGY RESEARCH AND TREATMENT. 42, p. 96. Karger, Basel (2019).
Wille, K., Stegelmann, F., Busen, H., Fuchs, Christiane, Schauer, S., Sadjadian, P., Becker, T., Kolatzki, V., Doehner, H., Doehner, K., and Griesshammer, M. “Cutaneous adverse events (CAE) in MPN patients with cytoreductive therapy are strongly associated with hydroxyurea (HU): results from a prospective non-interventional study”. ONCOLOGY RESEARCH AND TREATMENT. Basel: Karger, 2019.Vol. 42. 96.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Suchen in

Google Scholar